Humana: Barclays raises assessment and price target citing upcoming Medicare ratings

Humana benefits as a healthcare provider significantly from its focus on US Medicare programs. Barclays upgrades the stock to "Overweight" with a target price of 515 USD. Analysts expect higher profitability for core contracts due to the upcoming BY28 cycle. Focus on government health programs drives revenue Humana's (HUM) business model is based on over 80% of government contracts, primarily under the Medicare Advantage programs for seniors. This focus ensures a steady demand given the demographic shift. In the first quarter of 2026,...